Dr. Siddharth Sharma

Associate Professor

Specialization

Cancer Biology

Email

siddharthsharma.phd@thapar.edu

Specialization

Cancer Biology

Email

siddharthsharma.phd@thapar.edu

ACADEMIC PREPARATION

  1. 2007-2009, Post-Doctoral Fellow, Department of Pathology, Miller School of Medicine, University of Miami Florida, USA
  2. 2005-2006, Post-Doctoral Fellow, Department of Molecular and cellular biology University of Cape Town
  3. 2004, Ph.D; Department of Biotechnology, Panjab University, Chandigarh Biotechnology (Cancer genetics)
  4. 1998, M.Sc; Life Sciences School of life sciences Pondicherry Central University Pondicherry                         
  5. 1996, BSc; Botany; University of Madras, Madras

 

POSITIONS HELD

1. Thapar Institute of Engineering & Technology, Patiala (7 years)

  • Associate Professor, (July-2017-current) Department of Biotechnology,
  • Assistant Professor (July 2011-2017) Department of Biotechnology

2. Application-Scientist (August 2009-June 2011) in Flow Cytometry, Beckman Coulter Pvt. Ltd

3. Post-Doctoral Fellow (2007-2009), Department of Pathology, Miller School of Medicine, University of Miami Florida, USA

4. Post-Doctoral Fellow (2005-2006), Department of Molecular and cellular biology University of Cape Town        

5. Research Associate (Scientist Grade II) (2002-2004) Department of Biotechnology, National Institute of Pharmaceutical education and Research (NIPER), Mohali

6. Research Scientist Ranbaxy Research Laboratory, Gurgaon

PROFESSIONAL SYNOPSIS

Over 14 years of Research experience in the area of molecular biology and cell biology. I obtained my Ph.D on a research project titled “Studies on the molecular alterations in the pathogenesis of small cell and non-small cell lung carcinomas”. This work involved detecting novel markers if any for early risk assessment and diagnosis of lung cancers. I further enhanced my research domain by working as an RA in NIPER, where I worked on the role of oxidative stress genes and risk towards oral carcinogenesis in North Indian populations. Initial work was on the caloric restriction of yeasts and its influence on aging, apart from this I also was involved in the cloning of phytase gene from AspergiI!us niger var. teigham in Pichia pstoris. After my stint in NIPER I moved to the pharma industry and joined Ranbaxy laboratories where I was involved in the cloning of ion channel genes and also Muscaranic receptor genes. Here I was involved in the cloning of cDNAs encoding for five Muscaranic subtypes (M1-M5) in different promoters in various eukaryotic vectors and its expression in different mammalian cell lines.

I then joined as a post-doctoral fellow in an industry sponsored in the Centre for Proteomics and Genomic  Research  in  the Institute  of  Infectious  Diseases  and  Molecular  Medicine, University of  Cape Town, South Africa. My collaborative project with Procognia (a London based proteomics company) was focused on cloning and expression of genes involved in drug metabolism in E.coli and Baculovirus for the creation of functional protein array.  I did my second post-doctoral research in the Department of Pathology, University of Miami Miller School of Medicine. Here I worked in the area of hematopoietic stems cells and used flow cytometry approach to simultaneously measure Electronic Cell Volume and marker expression to study stem cells in HPC-A samples for patients undergoing bone marrow transplantation.

RESEARCH DOMAINS (Medical Biotech): SNP related Risk assessment, Biomarker discovery, Polymorphism relation to cancer clinical outcomes, Molecular markers for lung cancer prognosis, Protein Microarrays.

AREA OF RESEARCH:

My lab is focused on Molecular profiling of lung cancer – a) Risk assessment (b) Biomarker expression related especially clinical outcomes.

(a)We have assessed, and published data related to the molecular epidemiology of lung cancer. Our primary area of research is related to the genetic epidemiology of lung tumors in North Indian population. Since genetic background has an important role in susceptibility to complex diseases including lung cancer, and the genetic contribution to disease phenotypes varies between populations, our work has helped us to identify key Single Nucleotide Polymorphism (SNPs) which are associated with individual susceptibility for lung carcinogenesis. Secondly, we have also identified the role of